Case Studies

#Drug discovery #JAK inhibitor #Molecular dynamics #Proteins

A Free Energy Perturbation (FEP) study: Identifying ‘new’, active ligands for TYK2

In this Case Study, we test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system. Computational methods used include: Molecular Dynamics (MD) Water analysis solving the Ornstein-Zernike equation (3D-RISM) Alignment of ligands for FEP (Conformation Hunt… Read More

#Case Studies #Resources

#Drug discovery

Case Study – A Free Energy Perturbation (FEP) study: Identifying ‘new’, active ligands for TYK2

In this case study, we test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system.   Computational methods used include: Molecular Dynamics (MD) Water analysis solving the Ornstein-Zernike equation (3D-RISM) Alignment of ligands for FEP (Conformation… Read More

#Case Studies

#Therapeutic Antibodies

Case Study – Synthesis & Characterization of Trastuzumab-Based ADCs Using Fluorescent & Cytotoxic Payloads

Delve into our case studies on ADC Synthesis, Development, and Characterization, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow cytometry and internalization assays confirmed antigen targeting and cellular uptake. Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy… Read More

#Case Studies

#Automation / robotics

Case Study: Automating Cell-Based Assays to Determine Viral Vector Titer

In this Case Study, Oxford Biomedica, an innovative global gene and cell therapy company, describes: The automated system used for a 10-day cell-based workflow required for an analytical test to determine viral vector titer The advantages of Hamilton’s CECULA Graphical User Interface (GUI) for the planning of long-term cell-based assays… Read More

#Case Studies

#Drug discovery

Case Study: Streamline Preclinical Drug Discovery: PBMC-Humanised Mouse Models

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More

#Case Studies